Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04233827 · ClinicalTrials.gov registry record

Mobile Biosensor for Measuring Vital Signs in Healthcare and Home Settings

A clinical trial, sponsored by University of California, San Diego.

Completed
Registry status
361
Enrollment target

NCT04233827: Completed study, sponsored by University of California, San Diego.

NCT04233827 is a clinical trial that has completed, run by University of California, San Diego. The registered enrollment target is 361 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04233827 has completed, sponsored by University of California, San Diego.

COMPLETED
Registry status
361 participants
Enrollment target

Study Summary

This study will record vital signs (heart rate and blood oxygen levels) using a new cell phone integrated biosensor and compare it to routine measurements carried out in the clinics and hospital at UCSD. Cell phones will be given to a selected group of subjects for use at home and data collected.

Primary Outcome

The accuracy of the vital sign (HR and SpO2) readings collected by Maxim biosensor compared to standard of care Welch-Allyn Spot Vital Sign monitor.

Trial Details

FieldValue
Enrollment Target 361 participants
Start Date 2016-10-20
Est. Completion 2022-12-31
University of California, San Diego

775 total trials

What the finished NCT04233827 record still lists

NCT04233827 is an observational study that tracks outcomes without assigning an intervention. The registered 361 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT04233827 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04233827 about?

NCT04233827 is a clinical study titled "Mobile Biosensor for Measuring Vital Signs in Healthcare and Home Settings". This study will record vital signs (heart rate and blood oxygen levels) using a new cell phone integrated biosensor and compare it to routine measurements carried out in the clinics and hospital at UCSD. Cell phones will be given to a selected group of subjects for use at home and data collected.

What is the current status of trial NCT04233827?

This trial is currently completed. The enrollment target is 361 participants. The study started on 2016-10-20. Estimated completion is 2022-12-31.

Who is sponsoring clinical trial NCT04233827?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05533697 · 361 participants · Phase 1

    Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

  • NCT04988555 · 362 participants · Phase 1

    A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

  • NCT05536141 · 362 participants · Phase 1

    A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  • NCT06534983 · 362 participants · Phase 2

    A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04233827, the US trial registry maintained by the National Library of Medicine. NCT04233827 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.